A panel of experts that advises the CDC on the use of vaccines in the U.S. has voted to approve third, booster doses for certain groups who initially got two doses of the Pfizer-BioNTech vaccine.
in the U.S. voted Thursday to approve third, booster doses of the Pfizer-BioNTech vaccine – but only for certain groups.Adults ages 65 and up and residents of long-term care facilities
The Advisory Committee on Immunization Practices considered, but narrowly rejected, boosters for a fourth group: adults ages 18 to 64 who live or work in a place where the burden of COVID-19 and risk of transmission are high. That would have included healthcare or other frontline workers and people who live in group settings such as homeless shelters and prisons.In making the recommendations, the committee left out health care workers.
The committee saw data showing that all of the vaccines remain highly protective against hospitalization and death for all age groups, though protection against getting sick with COVID has waned slightly over time and with the dominance of the more contagious ACIP Chair Grace Lee, MD, a pediatric infectious disease specialist at Stanford, said she had cared for children who had died of COVID.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
COVID-19 live updates: CDC advisory panel expected to vote on Pfizer booster within hoursThe CDC’s independent advisory panel is set to vote this afternoon on which Americans are eligible now for a Pfizer booster.
Read more »
CDC advisory panel votes to recommend Pfizer boosters for people 65 and olderBREAKING: The CDC's independent advisory panel has unanimously voted to recommend booster doses of Pfizer's COVID vaccine for people aged 65 and older, along with long-term care facility residents, at least six months after their second dose.
Read more »
CDC panel recommends Pfizer boosters for high-risk individuals, people 65 and upA key panel at the Centers for Disease Control and Prevention on Thursday recommended the Pfizer-BioNTech coronavirus booster shots for people 65 years old and older, as well as those at high risk of severe COVID-19. Why it matters: The approval is the near-final step in making the booster shots available to tens of millions of Americans, and comes a day after the FDA approved Pfizer boosters for the two groups. CDC director Rochelle Walensky is expected to accept the recommendation.Stay on top
Read more »
CDC Panel Recommends Pfizer Covid-19 Boosters for Seniors, Certain Adults With Underlying Medical ConditionsA CDC panel recommended Pfizer Covid-19 boosters for seniors and some adults with underlying medical conditions, but not adults at high risk of exposure at work
Read more »
FDA authorizes Pfizer-BioNTech booster shot for elderly, people at high risk of severe Covid-19Pfizer-BioNTech booster shots are now authorized by the FDA for people 65 and older and for certain high-risk adult populations
Read more »
U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on ThursdayThe CDC's Advisory Committee on Immunization Practices (ACIP) is meeting on Sept 22-23 to discuss which Americans should get the third vaccine shot, should it be authorized for use by the Food and Drug Administration. Pfizer has asked the FDA to approve the third shot for all people aged 16 and over, but a panel of outside advisors to the FDA last Friday said there was only evidence for a shot being needed by people aged 65 and older.
Read more »